Invitae Bankruptcy (No. 24-11362): Third Circuit Affirms Plan Rulings, NVTA Stock Cancelled, Wind-Down Into 2027
ElevenFlo ·
Invitae's liquidating Chapter 11 plan took effect August 7, 2024 Dkt. 1292 · p. 1, after Labcorp bought the business for a $239 million base cash price Dkt. 614 · p. 21. On October 29, 2026, the bankruptcy docket received the Third Circuit's judgment affirming the District Court in the creditors' committee appeal Dkt. 1291. Invitae (NVTA) stock was cancelled with no distribution Dkt. 913 · p. 99. A hearing on Humana's administrative claim is set for December 17, 2026 Dkt. 1300 · p. 2.
Jump to section
Invitae sold its genetic testing business to Labcorp in 2024 and is winding down under a liquidating plan. This page covers what shareholders and creditors received, the end of the committee appeal and what is still pending.
Invitae Corporation and five subsidiaries filed for Chapter 11 on February 13, 2024 in the U.S. Bankruptcy Court for the District of New Jersey Dkt. 1292 · p. 11, Case No. 24-11362 before Judge Michael B. Kaplan Dkt. 913 · p. 132. The company sold substantially all of its assets to Labcorp Genetics Inc. after an auction, and the court approved the sale on May 7, 2024 Dkt. 614 · p. 21Dkt. 463. The plan was confirmed August 2, 2024 and became effective August 7, 2024 Dkt. 1292 · p. 1. Plan administrator Andrew Spirito now runs the wind-down Dkt. 1292 · p. 11.
The case's biggest fight, the unsecured creditors' committee's challenge to a 2023 debt exchange, has now lost in the bankruptcy court, the District Court and the Third Circuit, whose judgment affirming was docketed October 29, 2026 Dkt. 1291. Remaining work includes claims reconciliation, a Humana administrative-expense dispute, a genetic privacy class action that the court routed through the plan's gatekeeper process, and a hearing on closing the case set for March 25, 2027 Dkt. 1292 · p. 12Dkt. 1300 · p. 2Dkt. 1299 · p. 10Dkt. 1283 · p. 3.
| Debtors | Invitae Corporation and five subsidiaries Dkt. 1292 · p. 11 |
| Court and judge | U.S. Bankruptcy Court, District of New Jersey; Judge Michael B. Kaplan Dkt. 913 · p. 132 |
| Case number | 24-11362 (MBK), jointly administered Dkt. 914 · p. 1 |
| Petition date | February 13, 2024 Dkt. 1292 · p. 1 |
| Debt at filing | About $1.482 billion of debt obligations Dkt. 21 · p. 21 |
| Sale | Labcorp Genetics Inc., $239 million base cash price; sale order May 7, 2024 Dkt. 614 · p. 21 |
| Plan confirmed | August 2, 2024 Dkt. 1292 · p. 1 |
| Effective date | August 7, 2024 Dkt. 1292 · p. 1 |
| Stock | NYSE ticker NVTA; trading suspended February 6, 2024 Dkt. 21 · p. 24; cancelled under the plan Dkt. 913 · p. 99 |
| Plan administrator | Andrew Spirito Dkt. 1292 · p. 11 |
| Claims and noticing agent | Kurtzman Carson Consultants Dkt. 1292 · p. 2Dkt. 1140 · p. 1; case website veritaglobal.net/invitae Dkt. 1300 · p. 1 |
| Next hearings | December 17, 2026 (Humana claim) Dkt. 1300 · p. 2; March 25, 2027 (case closing) Dkt. 1283 · p. 3 |
What Happened to Invitae (NVTA) Stock
Invitae's common stock traded on the New York Stock Exchange under the ticker NVTA. On February 6, 2024, a week before the bankruptcy filing, the NYSE suspended trading and began delisting proceedings. Invitae had about 291.1 million shares outstanding at the petition date Dkt. 21 · p. 24.
The confirmed plan cancelled all equity interests on the effective date Dkt. 913 · p. 99, and holders received no recovery or distribution Dkt. 614 · p. 39. The plan administrator's report for the quarter ended September 30, 2026 lists $0 anticipated and $0 paid on equity interests Dkt. 1292 · p. 7. Holders of parent-company unsecured claims were projected to recover 0% on about $1,183.7 million of claims Dkt. 614 · p. 38; Invitae's 2028 convertible senior unsecured notes alone had $1.15 billion outstanding at filing Dkt. 21 · p. 24.
The Committee Appeal Ended With a Third Circuit Affirmance
In March 2023, Invitae exchanged $305.7 million of convertible unsecured notes due 2024 for $275.3 million of new secured Series A notes due 2028 and 14,219,859 shares, and sold $30 million of new secured Series B notes Dkt. 21 · p. 4. The unsecured creditors' committee called this an uptier transaction with Deerfield and other favored lenders made while Invitae was insolvent, and sought standing to sue for constructive and actual fraudulent transfer and breach of fiduciary duty. It said success would avoid the liens securing the 2028 senior secured notes and improve unsecured creditors' recoveries by hundreds of millions of dollars Dkt. 614 · p. 22.
The bankruptcy court denied the committee's standing motion on August 2, 2024 Dkt. 914 · p. 1, the day it confirmed the plan Dkt. 1292 · p. 1. On August 11, 2025, the District Court affirmed both orders, as supplemented by the bankruptcy court's findings on remand, and on September 5, 2025 the committee appealed to the Third Circuit Dkt. 1221 · p. 1. On October 29, 2026, the bankruptcy court docketed a copy of the Third Circuit's judgment affirming the District Court's order Dkt. 1291.
The plan administrator's October 30, 2026 report lists resolution of the committee appeal, along with receivables collection and retained causes of action, among the factors that recoveries depend on Dkt. 1292 · p. 12.
Who Has Been Paid
The disclosure statement projected that holders of about $335.6 million of 2028 senior secured notes claims would recover 91.0% to 94.8% Dkt. 614 · p. 36, and that convenience claims ($9.2 million) and subsidiary unsecured claims ($7.1 million) would be paid in full Dkt. 614 · p. 37. Through September 30, 2026, total cash disbursements since the effective date reached $176,500,018, including $2,193,120 in the latest quarter Dkt. 1292 · p. 2.
| Class | Anticipated under the plan | Paid to date |
|---|---|---|
| Administrative claims | $10,523,762 | $10,523,762 Dkt. 1292 · p. 7 |
| Secured claims | $311,335,049 | $303,129,909 Dkt. 1292 · p. 7 |
| Priority claims | $2,896,967 | $2,384,545 Dkt. 1292 · p. 7 |
| General unsecured claims | $16,778,621 | $4,000,000 Dkt. 1292 · p. 7 |
| Equity interests | $0 | $0 Dkt. 1292 · p. 7 |
The report says claims reconciliation is ongoing and that the final pool of allowed claims may be higher than shown Dkt. 1292 · p. 12. Professional fees and expenses approved and paid in the case total $60,185,238 Dkt. 1292 · p. 7.
| Firm | Approved and paid |
|---|---|
| Kirkland & Ellis LLP | $20,108,172 Dkt. 1292 · p. 2 |
| White & Case LLP | $13,621,104 Dkt. 1292 · p. 2 |
| Moelis & Co | $12,140,161 Dkt. 1292 · p. 2 |
| FTI Consulting Inc. | $6,054,127 Dkt. 1292 · p. 2 |
| Ducera | $3,638,490 Dkt. 1292 · p. 2 |
| Province | $3,085,129 Dkt. 1292 · p. 2 |
| Cole Schotz P.C. | $623,109 Dkt. 1292 · p. 2 |
| Porzio, Bromberg & Newman | $601,578 Dkt. 1292 · p. 2 |
| Deloitte Tax LLP (non-bankruptcy) | $222,705 Dkt. 1292 · p. 4 |
| Kurtzman Carson Consultants | $90,663 Dkt. 1292 · p. 2 |
| Total | $60,185,238 Dkt. 1292 · p. 7 |
The Genetic Privacy Lawsuit and the Gatekeeper Order
On June 11, 2026, B.W., the representative plaintiff in an Illinois class action, sued the Debtors and Labcorp under the Illinois Genetic Information Privacy Act, alleging that Invitae transferred patient genetic data to Labcorp without prior authorization. The wind-down debtors moved to enforce the plan, the confirmation order and the sale order Dkt. 1299 · p. 3.
In a November 5, 2026 memorandum opinion and order, the court granted the motion in part. B.W. may not pursue claims against the Debtors and Labcorp in a way inconsistent with the order, the sale order, the plan and the confirmation order, and must file an adversary proceeding in the bankruptcy court under the plan's gatekeeper provision. The court denied, without prejudice, the request to rule that the claims were released and to bar B.W. from asserting them Dkt. 1299 · p. 10, because the record does not establish when the data transfer happened Dkt. 1299 · p. 9.
Timing is the open question. B.W. contends the transfer came after the August 7, 2024 effective date, while the Debtors point to the complaint's allegation that the acquisition was completed August 5, 2024, two days earlier Dkt. 1299 · p. 7. The court said discovery on the transfer date can proceed as part of a contested motion for relief from the gatekeeper provision Dkt. 1299 · p. 8.
What Is Still Pending
The hearing on a motion by Humana entities for allowance and payment of a Chapter 11 administrative expense claim is adjourned to December 17, 2026 at 10:00 a.m. Dkt. 1300 · p. 2. The hearing on the notice of intention to close the case was adjourned from September 3, 2026 to March 25, 2027 at 10:00 a.m. Dkt. 1283 · p. 3. The plan administrator lists December 31, 2027 as the anticipated date of its final decree application Dkt. 1292 · p. 7.
Natera Inc. has filed a verified adversary complaint seeking a declaratory judgment and injunctive relief. Natera says the Debtors rejected a January 17, 2024 asset purchase agreement between the two companies and that the plan administrator should be barred from litigating a dispute under that agreement in another court Dkt. 1140 · p. 2.
How Invitae Got Here
Founded in January 2010, Invitae delivered genetic testing across hereditary cancer, precision oncology and rare diseases, and its tests had been taken by more than 4.4 million patients Dkt. 21 · p. 2. Between 2019 and 2021 it made thirteen acquisitions that increased its funded debt obligations by about $1.5 billion and raised cash burn Dkt. 21 · p. 3. At the petition date it owed about $1.482 billion Dkt. 21 · p. 21.
The auction opened April 17, 2024 and concluded April 24, 2024, when Labcorp Genetics Inc. was named the purchaser. Its bid included a base purchase price of $239 million in cash plus non-cash consideration, including keeping most employees' jobs and paying certain cure costs Dkt. 614 · p. 21.
Key Dates
| Date | Event |
|---|---|
| February 6, 2024 | NYSE suspends trading in NVTA Dkt. 21 · p. 24 |
| February 13, 2024 | Chapter 11 petitions filed Dkt. 1292 · p. 11 |
| April 17 and 24, 2024 | Auction; Labcorp named purchaser Dkt. 614 · p. 21 |
| May 7, 2024 | Sale order entered Dkt. 614 · p. 21 |
| August 2, 2024 | Plan confirmed; standing motion denied Dkt. 1292 · p. 1Dkt. 914 · p. 1 |
| August 7, 2024 | Plan effective Dkt. 1292 · p. 1 |
| August 11, 2025 | District Court affirms Dkt. 1221 · p. 1 |
| September 5, 2025 | Committee appeals to the Third Circuit Dkt. 1221 · p. 1 |
| June 11, 2026 | B.W. genetic privacy suit filed in Illinois Dkt. 1299 · p. 3 |
| October 29, 2026 | Third Circuit judgment affirming docketed Dkt. 1291 |
| November 5, 2026 | Gatekeeper opinion and order Dkt. 1299 · p. 10 |
| December 17, 2026 | Humana administrative claim hearing Dkt. 1300 · p. 2 |
| March 25, 2027 | Hearing on notice of intention to close the case Dkt. 1283 · p. 3 |
| December 31, 2027 | Anticipated final decree application Dkt. 1292 · p. 7 |
Frequently Asked Questions
Did Invitae shareholders get anything?
No. The plan cancelled all equity interests Dkt. 913 · p. 99, and the latest post-confirmation report shows $0 paid on them Dkt. 1292 · p. 7.
Did the Third Circuit rule on the committee's appeal?
Yes. A copy of the Third Circuit's judgment affirming the District Court's order was docketed October 29, 2026 Dkt. 1291. The District Court had affirmed the order denying standing and the confirmation order Dkt. 1221 · p. 1.
Who bought Invitae and for how much?
Labcorp Genetics Inc., for a base purchase price of $239 million in cash plus non-cash consideration Dkt. 614 · p. 21.
Where is the Invitae bankruptcy docket?
Case No. 24-11362 (MBK) in the U.S. Bankruptcy Court for the District of New Jersey, jointly administered Dkt. 914 · p. 1. The claims and noticing agent's case website is veritaglobal.net/invitae Dkt. 1300 · p. 1.
When will the case close?
A hearing on the notice of intention to close the case is set for March 25, 2027 Dkt. 1283 · p. 3, and the plan administrator lists December 31, 2027 as the anticipated date of its final decree application Dkt. 1292 · p. 7.
Sources
- Dkt. 21First Day DeclarationFiled Feb 14, 2024Feb 14, 2024
- Dkt. 463Sale OrderFiled May 7, 2024May 7, 2024
- Dkt. 614Notice of Filing Disclosure Statement Relating to the Amended Joint Plan of Invitae Corporation and Its Debtor Affiliates Pursuant to Chapter 11 of the Bankruptcy Code (Filed by Michael D. Sirota on Behalf of Invitae Corporation)Filed Jun 11, 2024Jun 11, 2024
- Dkt. 913Findings of Fact, Conclusions of Law, and Order Confirming the Third Amended Joint Plan of Invitae Corporation and its Debtor Affiliates Pursuant to Chapter 11 of the Bankruptcy CodeFiled Aug 2, 2024Aug 2, 2024
- Dkt. 914Order Denying the Official Committee of Unsecured Creditors' Motion for (I) Leave, Standing, and Authority to Commence and Prosecute Certain Claims and Causes of Action on Behalf of the Debtors' Estates and (II) Exclusive Settlement AuthorityCited at p. 1 · Filed Aug 2, 2024Aug 2, 2024
- Dkt. 1140Verified Adversary Complaint [Adversary case 25-01015. Complaint by Natera Inc. against Invitae Corporation]Filed Jan 21, 2025Jan 21, 2025
- Dkt. 1221Notice of Appeal to the United States Court of Appeals for the Third CircuitCited at p. 1 · Filed Sep 5, 2025Sep 5, 2025
- Dkt. 1283Adjournment Request DeterminationCited at p. 3 · Filed Aug 31, 2026Aug 31, 2026
- Dkt. 1291COPY OF UNITED STATES COURT OF APPEALS JUDGMENT AFFIRMING ORDER OF THE UNITED STATES DISTRICT COURT (related document: [1221] COPY OF DISTRICT COURT NOTICE OF APPEAL BY THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS TO THE UNITED STATES COURT OF APPEALS (RE: CA#24-CV-08550-RK)). Signed on 10/29/2026. (jpp)Filed Oct 29, 2026Oct 29, 2026
- Dkt. 1292Quarterly Wind-Down ReportFiled Oct 30, 2026Oct 30, 2026
- Dkt. 1299Gatekeeper Enforcement OrderFiled Nov 5, 2026Nov 5, 2026
- Dkt. 1300Humana Claim Hearing DateFiled Nov 6, 2026Nov 6, 2026